SABCS 2022 - Camizestrant May Be Superior to Fulvestrant in Patients With HR+/HER2- BC

Watch Now SABCS 2022 - Camizestrant May Be Superior to Fulvestrant in Patients With HR+/HER2- BC

SABCS 2022 : Genetic Profiling (POLAR) for Patients with BC may Safely Omit Radiation

Watch Now SABCS 2022 : Genetic Profiling (POLAR) for Patients with BC may Safely Omit Radiation

SABCS 2022 - Race and Clinical Outcomes in the RxPONDER Trial

Watch Now SABCS 2022 -  Race and Clinical Outcomes in the RxPONDER Trial

ESMO 2022 - TROPiCS-02: Final results phase III study in MBC

Watch Now ESMO 2022 - TROPiCS-02: Final results phase III study in MBC

ASCO 2022 - MAINTAIN Trial of Fulvestrant/Exemestane +/- Ribociclib After Progression in mBC

Watch Now ASCO 2022 - MAINTAIN Trial of Fulvestrant/Exemestane +/- Ribociclib After Progression in mBC